C12N 2799/028
Where the vector is derived from a herpesvirus
Official title: where the vector is derived from a herpesvirus
C12N2799/028 (Where the vector is derived from a herpesvirus) appears on 63 US grants and 60 published applications in this corpus.
Search patents in C12N- Granted patents
- 63
- Published applications
- 60
- Assignees
- 43
- Inventors
- 114
- Latest grant
- 1 Dec 2020
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 4 | 0 |
| 1999 | 6 | 0 |
| 2000 | 1 | 0 |
| 2001 | 3 | 0 |
| 2002 | 6 | 8 |
| 2003 | 3 | 5 |
| 2004 | 2 | 5 |
| 2005 | 3 | 5 |
| 2006 | 4 | 4 |
| 2007 | 1 | 3 |
| 2008 | 5 | 6 |
| 2009 | 2 | 3 |
| 2010 | 4 | 3 |
| 2011 | 5 | 3 |
| 2012 | 3 | 3 |
| 2013 | 0 | 3 |
| 2014 | 0 | 0 |
| 2015 | 2 | 1 |
| 2016 | 2 | 3 |
| 2017 | 3 | 3 |
| 2018 | 2 | 0 |
| 2019 | 0 | 1 |
| 2020 | 1 | 0 |
| 2021 | 0 | 0 |
| 2022 | 0 | 1 |
By publication year. Applications have been published since 2001.
Recent patents
- TRPV1 modulatory gene product that affects TRPV1-specific pain behavioral responses identified in a functional screen of an HSV-based cDNA library1 Dec 2020US 10,851,354 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- TRPV1 modulatory gene product that affects TRPV1-specific pain behavioral responses identified in a functional screen of an HSV-based cDNA library25 Dec 2018US 10,160,959 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Pharmaceutical composition comprising Nanog shRNA, and method of using Nanog shRNA to treat cancer5 Jun 2018US 9,988,631 B2The United States of America, as represented by the Secretary, Dept. of Health and Human Services
- Targeting of herpes simplex virus to specific receptors31 Oct 2017US 9,803,006 B2The University of Chicago
- Method for treating bleeding disorders16 May 2017US 9,650,431 B2Bayer HealthCare LLC
- Nerve regeneration4 Aug 2022US 2022/0241433 A1Kolon Tissuegene, Inc.
- Trpv1 modulatory gene product that affects trpv1-specific pain behavioral responses identified in a functional screen of an hsv-based cdna library26 Sep 2019US 2019/0292530 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
- Trpv1 modulatory gene product that affects trpv1-specific pain behavioral responses identified in a functional screen of an hsv-based cdna library5 Oct 2017US 2017/0283782 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
- Factor viii glycoforms21 Sep 2017US 2017/0267745 A1Bayer HealthCare LLC
- Pharmaceutical composition comprising nanog shrna, and method of using nanog shrna to treat cancer9 Feb 2017US 2017/0037406 A1The USA, as represented by the Secretary, Dept. of Health and Human Services
Most cited
By later US patents
- Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma287US 5,776,456 AIDEC Pharmaceuticals Corporation · 1998
- Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma152US 5,843,439 A1998
- Anti-CD20 antibodies147US 7,422,739 B2Biogen Idec Inc. · 2008
- Chimeric and radiolabelled antibodies specific to human CD20 antigen and use thereof for treatment of B-cell lymphoma130US 6,399,061 B1IDEC Pharmaceutical Corporation · 2002
- Stabilized external guide sequences129US 6,057,153 AYale University · 2000